Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Pipeline Snapshot as of November 2, 2021
- Discovery Projects
- 27Phase 1
- 29Phase 2
- 29Phase 3
- 9Registration
- Total94
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Comirnaty (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S. - 12 to 15 years of age) (E.U. - 12 years of age and older) | Registration | Product Enhancement | Vaccine |
Comirnaty (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection Booster (in collaboration with BioNTech)(FAST TRACK, U.S.; EU)
Project advanced | Registration | Product Enhancement | Vaccine |
Comirnaty (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S.; EU - 5 to 11 years of age)
Project advanced | Registration | Product Enhancement | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (adult) (E.U.) | Registration | New Molecular Entity | Vaccine |
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Primary Clostridioides difficile infection (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (pediatric) (BREAKTHROUGH, FAST TRACK) | Phase 3 | Product Enhancement | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (maternal) (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (adolescent and young adults) | Phase 3 | New Molecular Entity | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (older adult)
Project advanced | Phase 3 | Product Enhancement | Vaccine |
Comirnaty (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (maternal)
Project advanced | Phase 3 | Product Enhancement | Vaccine |
Comirnaty (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (children 2 to 4?years of age)
Project advanced | Phase 3 | Product Enhancement | Vaccine |
Comirnaty (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (infants 6 months to <24 months)
Project advanced | Phase 3 | Product Enhancement | Vaccine |
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants and children) | Phase 2 | New Molecular Entity | Vaccine |
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive Group B Streptococcus Infection (maternal) (FAST TRACK) | Phase 2 | New Molecular Entity | Vaccine |
PF-07307405 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Lyme disease (FAST TRACK) | Phase 2 | New Molecular Entity | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (infants) | Phase 2 | Product Enhancement | Vaccine |
PF-07252220 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | Influenza (adults)
Project advanced | Phase 1 | New Molecular Entity | Vaccine |
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
![iStock-1199449498_380x300[1].jpg](https://cdn.pfizer.com/pfizercom/styles/style_300_170/s3/2021-09/iStock-1199449498_380x300%5B1%5D.jpg?pYyJpQdhyvaU22v13JPyau8ro2rGk0CR&itok=pJGCW7Vt)
